Longitude Capital’s cover photo
Longitude Capital

Longitude Capital

Venture Capital and Private Equity Principals

Menlo Park, CA 6,345 followers

About us

Longitude Capital specializes in making venture growth investments in biotechnology, medical technology and health solutions companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. Longitude Capital invests in both privately held and publicly traded life science companies through a variety of investment approaches. Media Contact: Maggie Jamison mjamison@longitudecapital.com

Website
http://www.longitudecapital.com
Industry
Venture Capital and Private Equity Principals
Company size
11-50 employees
Headquarters
Menlo Park, CA
Type
Partnership
Founded
2006

Locations

Employees at Longitude Capital

Updates

  • Franciscan Health is partnering with Longitude portfolio company Ceribell │ AI-Powered Point-of-Care EEG to transform neurological care and expand access to rapid EEG across five hospitals. The Ceribell System enables rapid seizure detection and continuous monitoring, empowering frontline clinicians to quickly make critical treatment decisions and improve patient outcomes. Learn more about this collaboration and its impact below. 

    View organization page for Franciscan Health

    26,108 followers

    Franciscan Health is transforming neurological care for critically ill patients at its hospitals across Northwest Indiana and Chicago’s South Suburbs with the adoption of the Ceribell System, an FDA-cleared electroencephalography (EEG) device powered by artificial intelligence (AI). Franciscan Health Crown Point, Dyer, Michigan City, Munster and Olympia Fields all employ the device in their hospitals. The technology was first implemented at Franciscan Health Michigan City in January 2024 before being adopted at the Crown Point hospital in September 2024, in Olympia Fields in December 2024 and in the Dyer and Munster hospitals this spring. Designed for rapid seizure detection and continuous monitoring, this groundbreaking technology enables local hospital teams to quickly make critical treatment decisions and potentially provide better outcomes for patients at risk of non-convulsive seizures. These seizures occur without obvious symptoms, making them difficult to detect and often delaying treatment. Without prompt management with anti-seizure medication, non-convulsive seizures can become more difficult to manage. Similar to stroke, "time is brain" for seizures and prompt diagnosis and intervention are critical as treatment efficacy declines with every hour of delay. The Ceribell System includes an easy-to-apply headband, a portable recorder and intuitive AI-driven software. Setup takes less than 5 minutes, giving clinicians fast access to EEG data for timely, informed decision making. A recent retrospective analysis found that compared to conventional EEG, initial assessment with Ceribell was associated with a median reduction of ICU stay by four days. “For our patients it provides rapid, bedside EEG to help detect seizures in various clinical presentations,” said Franciscan Health Olympia Fields Medical Director of Emergency Services Derwin Philip, MD. “It not only helps for faster diagnosis and treatment, but also for improved clinical outcomes, overtreatment avoidance and unnecessary admissions or transfers.” This technology is not meant to replace conventional EEG monitoring. Rather, it is a complementary solution that enables expanded EEG coverage throughout the hospital. “It empowers clinicians to make more informed decisions at the bedside, improving outcomes for patients with various medical, neurological and psychiatric conditions,” said Franciscan Health Crown Point Vice President of Medical Affairs Ryan Misek, DO, FACOEP, FACEP, who is also an emergency room physician. “This technology helps bridge the gap between immediate care and in-depth analysis, enhancing both efficiency and accuracy in the emergency department and critical care settings.”

  • Kristen Fortney, CEO and co-founder of Longitude portfolio company BioAge Labs, recently spoke at the 2025 Paul F. Glenn/AFAR Conference on the Biology of Aging, highlighting the company's approach, which leverages over 50 years of longitudinal human aging data to identify novel therapeutic targets for metabolic diseases. Learn more at https://bioagelabs.com/ 

    View organization page for BioAge Labs

    17,933 followers

    Today, our CEO Kristen Fortney is speaking at the 2025 Paul F. Glenn/AFAR Conference on the Biology of Aging, an annual meeting that brings together leading researchers advancing our understanding of aging biology and its therapeutic applications. Her talk, "From Human Data to Therapeutics for Aging-Related Diseases,” showcases BioAge's approach: leveraging over 50 years of longitudinal human aging data to identify novel therapeutic targets for metabolic diseases. By studying molecular changes that drive healthy versus accelerated aging, we discover pathways that address root causes rather than symptoms. We're excited to share how our platform reveals promising targets for the next generation of obesity and metabolic disease treatments. We believe this data-driven approach represents the future of developing therapies that meaningfully extend healthspan.

    • No alternative text description for this image
  • Congratulations to the FIRE1 team on completing enrollment in the next phase of the company's EFS. Learn more about the system that FIRE1 is developing for heart failure management at https://fire1foundry.com/

    View organization page for FIRE1

    4,300 followers

    Exciting milestone! 🎉 We are pleased to announce the successful completion of enrollment in the next phase of our EFS. This important milestone would not have been possible without the commitment and collaboration of our dedicated investigators, research coordinators, clinical partners, and above all, the patients who chose to participate. We are deeply grateful for your trust and contributions! The completion of this enrollment phase marks continued progress in our mission to develop transformative solutions for heart failure management. Each step forward brings us closer to helping millions of individuals living with heart failure reclaim a sense of stability, confidence, and normalcy in their daily lives - get their Normal back! #Norm #HeartFailure #HFpEF #HFrEF #ClinicalResearch #Innovation #Gratitude #MedTech

    • No alternative text description for this image
  • Longitude portfolio company Lexeo Therapeutics has received FDA Breakthrough Therapy designation for LX2006 – a gene therapy for Friedreich ataxia (FA), based on promising cardiac and neurologic data. “We are highly encouraged by the impact of LX2006 on key measures of cardiac health, especially given the lack of treatments for FA cardiomyopathy today, which is the leading cause of death in FA. We are also optimistic about the improvements we have observed in functional measures of FA more broadly, and we look forward to a continued partnership with the FDA through the Breakthrough Therapy designation and the CDRP program as we work to bring this potential treatment to patients as quickly as possible.” – Dr. Sandi See Tai, Chief Development Officer of Lexeo Therapeutics Read more at https://lnkd.in/egqDbEeq

    • No alternative text description for this image
  • Longitude portfolio company On Belay Health Solutions helps primary care teams deliver the best possible care for their patients while also ensuring their own well-being and sustainability as a practice. Read how nurse care manager Karen Conway and social worker Kerry Slattery with On Belay supported a retired Massachusetts nurse through a health ordeal: https://lnkd.in/eiJ4_sDn #PatientStories

  • Xingjuan (Jane) Chao, CEO of Longitude portfolio company Ceribell │ AI-Powered Point-of-Care EEG, has been named one of The Healthcare Technology Report's top 25 Medtech Executives of 2025. Ceribell's technology combines portable hardware with AI-powered algorithms to enable rapid diagnosis and continuous monitoring of patients in acute care settings. Currently used in ICUs and emergency rooms across the U.S., Ceribell aims to establish its system as the standard of care for EEG. Learn more about Jane and read about the other key figures advancing healthcare technology: https://lnkd.in/gxzGR8_q

  • Longitude portfolio company Endogenex recently reported positive findings from studies of its endoscopic procedure aimed at transforming diabetes care. The company's system aims to deliver a substantial and durable reduction in insulin resistance and improvement in beta cell function. Learn more about Endogenex's ReCET technology in MassDevice from Sean Whooley: https://lnkd.in/eU8dvrnp

  • Longitude portfolio company Rapid Micro Biosystems is a leader in automated microbial contamination detection for pharmaceutical manufacturing — and is one of the best companies to work for in 2025, according to U.S. News & World Report. More on the company's recent awards below.

    View organization page for Rapid Micro Biosystems

    14,624 followers

    We’re honored to be named one of the 2025–2026 Best Companies to Work For by U.S. News & World Report. Rapid Micro Biosystems, Inc. has been recognized with three awards in this year’s ratings: ✔️ Best Companies to Work For – Overall ✔️ Best Companies to Work For – Health Care and Research ✔️ Best Companies to Work For – Northeast Region This recognition reflects the dedication and excellence of our entire team. Thank you for making Rapid Micro Biosystems a great place to work. #USNewsAwards #RapidMicroBio #AutomationInBiotech #TopEmployer

    • No alternative text description for this image

Similar pages

Browse jobs